Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 3/20 | 0.64 |
| ▸ | NAAA | Q02083 | 1/20 | 0.64 |
| ▸ | CNR1 | P21554 | 10/20 | 0.53 |
| ▸ | CNR2 | P34972 | 7/20 | 0.51 |
| ▸ | LDHA | P00338 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22564594 | 1.00 | DAGLA (0.64) | DAGLANAAACNR1CNR2LDHA | |
| SCHEMBL24132001 | 1.00 | DAGLA (0.64) | DAGLANAAACNR1CNR2LDHA | |
| SCHEMBL24703764 | 0.93 | DAGLA (0.62) | DAGLANAAACNR1CNR2LDHA | |
| SCHEMBL24703761 | 0.93 | DAGLA (0.62) | DAGLANAAACNR1CNR2LDHA | |
| SCHEMBL24704101 | 0.84 | DAGLA (0.57) | DAGLANAAACNR1CNR2LDHA | |
| SCHEMBL24299982 | 0.84 | TRPV1 (0.46) | DAGLANAAACNR1CNR2LDHA | |
| SCHEMBL24703680 | 0.81 | CNR2 (0.57) | DAGLANAAACNR1CNR2LDHA | |
| SCHEMBL23052897 | 0.81 | CNR2 (0.57) | DAGLANAAACNR1CNR2LDHA | |
| SCHEMBL22957097 | 0.81 | CNR2 (0.57) | DAGLANAAACNR1CNR2LDHA | |
| SCHEMBL13609362 | 0.81 | CNR2 (0.57) | DAGLANAAACNR1CNR2LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387352-A1 | CANNABINOID COMPOSITIONS AND METHODS OF USING FOR THE TREATMENT OF NON-EOSINOPHILIC INFLAMMATION AND INFLAMMATORY DISORDERS | MEDTERRA PHARMA LLC | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387352-A1 | CANNABINOID COMPOSITIONS AND METHODS OF USING FOR THE TREATMENT OF NON-EOSINOPHILIC INFLAMMATION AND INFLAMMATORY DISORDERS | CNR2, CNR1, FAAH2 | DAGLA 191/4885NAAA 281/4885CNR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.